• Je něco špatně v tomto záznamu ?

Standard error of measurement and smallest detectable change of the Sarcopenia Quality of Life (SarQoL) questionnaire: An analysis of subjects from 9 validation studies

A. Geerinck, V. Alekna, C. Beaudart, I. Bautmans, C. Cooper, F. De Souza Orlandi, J. Konstantynowicz, B. Montero-Errasquín, E. Topinková, M. Tsekoura, JY. Reginster, O. Bruyère,

. 2019 ; 14 (4) : e0216065. [pub] 20190429

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, validační studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006412

Grantová podpora
MC_U147585819 Medical Research Council - United Kingdom
MC_UP_A620_1014 Medical Research Council - United Kingdom
MC_UU_12011/1 Medical Research Council - United Kingdom
G0400491 Medical Research Council - United Kingdom
MC_U147585824 Medical Research Council - United Kingdom

OBJECTIVES: The Sarcopenia Quality of Life (SarQoL) questionnaire, a sarcopenia-specific patient-reported outcome measure, evaluates quality of life with 55 items. It produces 7 domain scores and 1 overall quality of life score, all between 0 and 100 points. This study aims to contribute to the interpretation of the SarQoL scores by calculating the standard error of measurement (SEM) and smallest detectable change (SDC) in a sample of subjects from 9 studies. METHODS: Subjects from 9 studies (conducted in Belgium, Brazil, Czech Republic, England, Greece, Lithuania, Poland and Spain) were included. The SEM, a measure of the error in the scores that is not due to true changes, was calculated by dividing the standard deviation of the difference between test and retest scores (SDdiff) by √2. The SDC, defined as change beyond measurement error, was calculated by multiplying SDdiff by 1.96. Bland-Altman plots were assessed for the presence of systematic errors. RESULTS: A total of 278 sarcopenic subjects, aged 77.67 ± 7.64 years and 61.5% women, were included. The SEM for the overall SarQoL score ranged from 0.18 to 4.20 points for the individual studies, and was 2.65 points when all subjects were analyzed together. The SDC for the overall score ranged from 0.49 to 11.65 points for the individual studies, and was 7.35 points for all subjects. The Bland-Altman plots revealed no systematic errors in the questionnaire. CONCLUSION: This study shows that, for individual subjects, a change in overall quality of life of at least 7.35 points (on a scale from 0 to 100) would have to be observed to confirm that a true change, beyond measurement error, has occurred. It also demonstrated that the SarQoL questionnaire is a precise instrument, with the observed scores within less than 3 points of the theoretical "true score".

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006412
003      
CZ-PrNML
005      
20200518132628.0
007      
ta
008      
200511s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0216065 $2 doi
035    __
$a (PubMed)31034498
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Geerinck, Anton $u World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Ageing, Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
245    10
$a Standard error of measurement and smallest detectable change of the Sarcopenia Quality of Life (SarQoL) questionnaire: An analysis of subjects from 9 validation studies / $c A. Geerinck, V. Alekna, C. Beaudart, I. Bautmans, C. Cooper, F. De Souza Orlandi, J. Konstantynowicz, B. Montero-Errasquín, E. Topinková, M. Tsekoura, JY. Reginster, O. Bruyère,
520    9_
$a OBJECTIVES: The Sarcopenia Quality of Life (SarQoL) questionnaire, a sarcopenia-specific patient-reported outcome measure, evaluates quality of life with 55 items. It produces 7 domain scores and 1 overall quality of life score, all between 0 and 100 points. This study aims to contribute to the interpretation of the SarQoL scores by calculating the standard error of measurement (SEM) and smallest detectable change (SDC) in a sample of subjects from 9 studies. METHODS: Subjects from 9 studies (conducted in Belgium, Brazil, Czech Republic, England, Greece, Lithuania, Poland and Spain) were included. The SEM, a measure of the error in the scores that is not due to true changes, was calculated by dividing the standard deviation of the difference between test and retest scores (SDdiff) by √2. The SDC, defined as change beyond measurement error, was calculated by multiplying SDdiff by 1.96. Bland-Altman plots were assessed for the presence of systematic errors. RESULTS: A total of 278 sarcopenic subjects, aged 77.67 ± 7.64 years and 61.5% women, were included. The SEM for the overall SarQoL score ranged from 0.18 to 4.20 points for the individual studies, and was 2.65 points when all subjects were analyzed together. The SDC for the overall score ranged from 0.49 to 11.65 points for the individual studies, and was 7.35 points for all subjects. The Bland-Altman plots revealed no systematic errors in the questionnaire. CONCLUSION: This study shows that, for individual subjects, a change in overall quality of life of at least 7.35 points (on a scale from 0 to 100) would have to be observed to confirm that a true change, beyond measurement error, has occurred. It also demonstrated that the SarQoL questionnaire is a precise instrument, with the observed scores within less than 3 points of the theoretical "true score".
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a kvalita života $7 D011788
650    _2
$a sarkopenie $x patologie $7 D055948
650    12
$a průzkumy a dotazníky $7 D011795
655    _2
$a časopisecké články $7 D016428
655    _2
$a validační studie $7 D023361
700    1_
$a Alekna, Vidmantas $u Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
700    1_
$a Beaudart, Charlotte $u World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Ageing, Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
700    1_
$a Bautmans, Ivan $u Frailty in Aging Research Group, Vrije Universiteit Brussel, Brussels, Belgium.
700    1_
$a Cooper, Cyrus $u MRC Environmental Epidemiology Unit, Southampton General Hospital, Southampton, United Kingdom.
700    1_
$a De Souza Orlandi, Fabiana $u Department of Gerontology, Federal University of São Carlos, São Carlos, SP, Brazil.
700    1_
$a Konstantynowicz, Jerzy $u Department of Pediatric Rheumatology, Immunology and Metabolic Bone Diseases, Medical University of Bialystok, Bialystok, Poland.
700    1_
$a Montero-Errasquín, Beatriz $u Department of Geriatrics, University Hospital Ramón y Cajal, Madrid, Spain.
700    1_
$a Topinková, Eva $u Department of Geriatrics and Gerontology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Tsekoura, Maria $u Department of Physical Therapy, School of Health and Welfare, Technological Institute of Western Greece, Aigio, Greece.
700    1_
$a Reginster, Jean-Yves $u World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Ageing, Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
700    1_
$a Bruyère, Olivier $u World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Ageing, Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 14, č. 4 (2019), s. e0216065
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31034498 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200518132628 $b ABA008
999    __
$a ok $b bmc $g 1525270 $s 1096468
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 14 $c 4 $d e0216065 $e 20190429 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a MC_U147585819 $p Medical Research Council $2 United Kingdom
GRA    __
$a MC_UP_A620_1014 $p Medical Research Council $2 United Kingdom
GRA    __
$a MC_UU_12011/1 $p Medical Research Council $2 United Kingdom
GRA    __
$a G0400491 $p Medical Research Council $2 United Kingdom
GRA    __
$a MC_U147585824 $p Medical Research Council $2 United Kingdom
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace